The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Karateev A.E.
Nasonova Research Institute of Rheumatology, Moscow, Russia
Nasonov E.L.
"Research Institute of rheumatology n. a. V. A. Nasonova"
Meloxicam in Russia: 20 years together
Journal: Therapeutic Archive. 2016;88(12): 149‑158
Views: 1625
Downloaded: 790
To cite this article:
Karateev AE, Nasonov EL. Meloxicam in Russia: 20 years together. Therapeutic Archive.
2016;88(12):149‑158. (In Russ.)
https://doi.org/10.17116/terarkh20168812149-158
Meloxicam is one of the most commonly used representatives of the group of nonsteroidal anti-inflammatory drugs prescribed in our country. It has been used in Russian clinical practice for 20 years and established itself as an effective and rather safe analgesic and anti-inflammatory medications. During this period almost 48 million packages of brand-name meloxicam have been sold; millions of people in our country have been successfully treated with this drug. During this period, there have been at least 29 Russian clinical trials of brand-name meloxicam, which covered 3,736 patients. In all the trials, meloxicam has demonstrated a good therapeutic potential (a substantial improvement in more than 75% of patients) and a low incidence of side effects, which averaged 6.4% (30.5% in the control groups). The good tolerability of brand-name meloxicam (Movalis) is confirmed by a total of 120 spontaneous reports of the adverse events due to this drug, which were sent to the Federal Service for Health Supervision in December 2008 to July 2015 (over the last 7 years). This number seems negligible (nearly 30 million packages) if the amount of meloxicam sold over the period is taken into account. Extensive experience in clinical practice with this drug and a wide series of national clinical trials support the good reputation of brand-name meloxicam among Russian physicians and patients. This review briefly gives the data of Russian and main foreign clinical trials of the therapeutic effect and safety of meloxicam.
Authors:
Karateev A.E.
Nasonova Research Institute of Rheumatology, Moscow, Russia
Nasonov E.L.
"Research Institute of rheumatology n. a. V. A. Nasonova"
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.